Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Royal Children's Hospital | OTHER |
| Royal Hospital For Women | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Babies aged 0 to 90 days with a suspected infection requiring treatment with vancomycin will be recruited. They will be randomised to receive vancomycin as an intermittent infusion (over 1 hour) or as a continuous infusion (over 24 hours). The hypothesis is that administering vancomycin as a continuous infusion will result in improved attainment of target concentrations in blood at steady state (when the drug is in equilibrium) compared to intermittent infusion.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intermittent infusion of vancomycin | No Intervention | Vancomycin will be administered intravenously over 1 hour. Doses will be given from one to four times a day according to corrected gestational age. | |
| Continuous infusion of vancomycin | Active Comparator | A loading dose of vancomycin will be given over 1 hour followed by a continuous infusion of vancomycin over a 24 hour period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Continuous infusion of vancomycin | Drug | Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of neonates achieving target vancomycin concentrations in blood at steady state (24-48 hours) | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Drug-related adverse effects | the proportion of drug-related adverse effects with CIV compared to IIV | 2 years |
| Time to achieve target levels | the time to and number of dose adjustments required to achieve target therapeutic vancomycin levels in blood |
Not provided
Inclusion Criteria:
- Neonates in the neonatal unit with an infection requiring treatment with vancomycin as determined by the treating physician.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Amanda Gwee, MBBS | Murdoch Childrens Research Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Royal Hospital for Women | Sydney | New South Wales | 2031 | Australia | ||
| The Royal Children's Hospital |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 30700564 | Derived | Gwee A, Cranswick N, McMullan B, Perkins E, Bolisetty S, Gardiner K, Daley A, Ward M, Chiletti R, Donath S, Hunt R, Curtis N. Continuous Versus Intermittent Vancomycin Infusions in Infants: A Randomized Controlled Trial. Pediatrics. 2019 Feb;143(2):e20182179. doi: 10.1542/peds.2018-2179. | |
| 30391914 | Derived |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D018805 | Sepsis |
| D007239 | Infections |
| D016470 | Bacteremia |
| ID | Term |
|---|---|
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 2 years |
| Clearance of vancomycin in young infants | Population pharmacokinetic modelling of vancomycin in young infants using NONMEM | 2 years |
| Volume of distribution of vancomycin in young infants | Population pharmacodynamics modelling of vancomycin in young infants using NONMEM | 2 years |
| Area under the concentration-time curve of vancomycin in young infants | Population pharmacodynamics modelling of vancomycin in young infants using NONMEM | 2 years |
| Time above the minimum inhibitory concentration of the bacteria for vancomycin in young infants | Population pharmacodynamics modelling of vancomycin in young infants using NONMEM | 2 years |
| Melbourne |
| Victoria |
| 3052 |
| Australia |
| Gwee A, Cranswick N, Donath SM, Hunt R, Curtis N. Protocol for a randomised controlled trial of continuous infusions of vancomycin to improve the attainment of target vancomycin levels in young infants: The VANC trial. BMJ Open. 2018 Nov 3;8(11):e022603. doi: 10.1136/bmjopen-2018-022603. |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |